|
May 27
|
Is Cytokinetics, Incorporated (NASDAQ:CYTK) the Best Mid-Cap Healthcare Stock To Buy Now?
|
|
May 24
|
Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday
|
|
May 23
|
Cytokinetics secures up to $575M in royalty deal, frustrating investors
|
|
May 23
|
Cytokinetics Announces Pricing of Public Offering of Common Stock
|
|
May 22
|
Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline
|
|
May 22
|
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
|
|
May 22
|
Cytokinetics Announces Proposed Public Offering of Common Stock
|
|
May 22
|
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
|
|
May 15
|
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024
|
|
May 13
|
Health Care Roundup: Market Talk
|
|
May 13
|
Cytokinetics Slumps Despite 'Pristine' Results For Bristol Myers-Rivaling Heart Drug
|
|
May 13
|
Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress
|
|
May 13
|
Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine
|
|
May 10
|
Cytokinetics Inc (CYTK) Reports Q1 2024 Earnings: Widening Losses Amid Expansive Clinical Trials
|
|
May 10
|
Cytokinetics First Quarter 2024 Earnings: Misses Expectations
|
|
May 9
|
Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Cytokinetics Inc (CYTK) Q1 2024 Earnings Call Transcript Highlights: Navigating Through ...
|
|
May 8
|
Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates
|
|
May 8
|
Cytokinetics Reports First Quarter 2024 Financial Results
|
|
May 8
|
Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy
|